Afraxis, Inc
Biotechnology ResearchCalifornia, United States2-10 Employees
Afraxis, Inc. operates as a contract research organization in the biotechnology sector, providing CNS-focused preclinical efficacy assessments (in vivo and in vitro), neurotoxicity testing, and Structure-Efficacy Relationship medicinal chemistry services. The company owns a patented platform called the Enhanced Spine Platform, which yields rapid, information-rich readouts of synaptic networks in brain tissue by integrating specialized neuronal labeling, advanced imaging, high-detail synapse analysis, and tailored big-data analytics. Originally developed to address Fragile-X syndrome drug discovery gaps, the ESP technology quickly became applicable to other CNS indications where dendritic spine abnormalities are relevant. Afraxis traces its ESP origins to the original Afraxis Holdings, founded in 2007 to pursue Fragile-X therapeutics based on work by Nobel laureate Susumu Tonegawa; the present Afraxis, Inc. emerged in 2013 as a spin-out dedicated to maturing ESP and related drug-discovery services. Based in San Diego, California, the company operates as a small research-focused organization, offering CNS expertise to support drug discovery programs.
1-888-653-2347 
support@leadiq.com 
